Standout Papers

Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell... 2021 2026 2022 2024199
  1. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial (2021)
    Nasser K. Altorki, Timothy E. McGraw et al. The Lancet Oncology

Immediate Impact

2 by Nobel laureates 1 from Science/Nature 56 standout
Sub-graph 1 of 22

Citing Papers

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
Ultralight crystalline hybrid composite material for highly efficient sequestration of radioiodine
2024 Standout
2 intermediate papers

Works of Ronald Scheff being referenced

Lung Cancer Stage Shift as a Result of COVID-19 Lockdowns in New York City, a Brief Report
2021
Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan
2017

Author Peers

Author Last Decade Papers Cites
Ronald Scheff 504 323 162 26 850
Maria Corinna Palanca-Wessels 435 110 117 32 850
Jacqueline Douglass 478 248 81 23 774
Suriya Jeyapalan 255 251 357 31 896
Deborah Forst 408 145 256 44 873
Armin Muigg 201 167 308 23 868
Bruce W. Dana 391 210 437 31 1.1k
Kelly McGlinchey 592 147 126 28 1.0k
Alessandra Felici 475 351 83 49 1.1k
Mayra Ramos 425 278 105 30 770
Nili Peylan‐Ramu 239 321 208 24 937

All Works

Loading papers...

Rankless by CCL
2026